联环药业：公司将继续深入推进“仿创结合”发展战略

Core Viewpoint - The company will continue to advance its "innovation and generics combination" development strategy, focusing on enhancing its traditional strengths while investing in emerging fields such as endocrinology, oncology, and respiratory systems [1] Business Strategy - The company aims to consolidate its traditional advantages and increase research and market investment in new areas [1] - It plans to promote the launch of core innovative drugs and expand internationally, enriching its high-value product pipeline [1] Market Expansion - The company will continue to expand into new retail and international markets to improve market penetration [1] - As a state-owned enterprise, it will respond to the strategic requirements of the parent group, leveraging its stable operational strategy, continuous innovation capabilities, and industry chain advantages [1] Financial Goals - The company seeks to achieve simultaneous growth in business scale and profitability, creating greater value for shareholders [1]